248 related articles for article (PubMed ID: 33552049)
41. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
[TBL] [Abstract][Full Text] [Related]
42. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
43. Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
Moskorz W; Cosmovici C; Jäger PS; Cadeddu RP; Timm J; Haas R
Br J Haematol; 2021 Jun; 193(5):941-945. PubMed ID: 33954988
[TBL] [Abstract][Full Text] [Related]
44. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
45. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept.
Aminu M; Daver N; Godoy MCB; Shroff G; Wu C; Torre-Sada LF; Goizueta A; Shannon VR; Faiz SA; Altan M; Garcia-Manero G; Kantarjian H; Ravandi-Kashani F; Kadia T; Konopleva M; DiNardo C; Pierce S; Naing A; Kim ST; Kontoyiannis DP; Khawaja F; Chung C; Wu J; Sheshadri A
Front Immunol; 2023; 14():1249511. PubMed ID: 37841255
[TBL] [Abstract][Full Text] [Related]
46. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
[TBL] [Abstract][Full Text] [Related]
47. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
[TBL] [Abstract][Full Text] [Related]
48. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
49. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
50. Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.
Wahlström J; Berlin M; Sköld CM; Wigzell H; Eklund A; Grunewald J
Thorax; 1999 Apr; 54(4):339-46. PubMed ID: 10092696
[TBL] [Abstract][Full Text] [Related]
51. Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review.
Jayakrishnan B; Al-Moundhri M; Burney I; Al-Hashami Z; Al-Bimani K
Adv Respir Med; 2022; 90(3):219-229. PubMed ID: 35731114
[TBL] [Abstract][Full Text] [Related]
52. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.
Lee SE; Wang F; Grefe M; Trujillo-Ocampo A; Ruiz-Vasquez W; Takahashi K; Abbas HA; Borges P; Antunes DA; Al-Atrash G; Daver N; Molldrem JJ; Futreal A; Garcia-Manero G; Im JS
Clin Cancer Res; 2023 May; 29(10):1938-1951. PubMed ID: 36988276
[TBL] [Abstract][Full Text] [Related]
53. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.
Yanagihara T; Hata K; Matsubara K; Kunimura K; Suzuki K; Tsubouchi K; Ikegame S; Baba Y; Fukui Y; Okamoto I
Elife; 2024 Apr; 12():. PubMed ID: 38607373
[TBL] [Abstract][Full Text] [Related]
54. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
55. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
[TBL] [Abstract][Full Text] [Related]
56. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
[TBL] [Abstract][Full Text] [Related]
57. Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.
Yu S; Liu C; Zhang L; Shan B; Tian T; Hu Y; Shao L; Sun Y; Ji C; Ma D
Int J Mol Sci; 2014 Jan; 15(2):1927-45. PubMed ID: 24473142
[TBL] [Abstract][Full Text] [Related]
58. Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
Larsen BT; Chae JM; Dixit AS; Hartman TE; Peikert T; Roden AC
Am J Surg Pathol; 2019 Oct; 43(10):1331-1340. PubMed ID: 31162288
[TBL] [Abstract][Full Text] [Related]
59. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder.
White DA; Rankin JA; Stover DE; Gellene RA; Gupta S
Am Rev Respir Dis; 1989 Jan; 139(1):18-21. PubMed ID: 2521438
[TBL] [Abstract][Full Text] [Related]
60. Bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in patients with acute leukemia.
Saito H; Anaissie EJ; Morice RC; Dekmezian R; Bodey GP
Chest; 1988 Oct; 94(4):745-9. PubMed ID: 3168571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
